1 – 10 of 29
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Deciphering the genetics and mechanisms of predisposition to multiple myeloma
(
- Contribution to journal › Article
- 2023
-
Mark
Use of Linked Nordic Registries for Population Studies in Hematologic Cancers : The Case of Multiple Myeloma
(
- Contribution to journal › Article
- 2022
-
Mark
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
(
- Contribution to journal › Article
-
Mark
Functional dissection of inherited non-coding variation influencing multiple myeloma risk
(
- Contribution to journal › Article
- 2021
-
Mark
Germline variants at SOHLH2 influence multiple myeloma risk
(
- Contribution to journal › Article
- 2020
-
Mark
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma : The HOVON-87/NMSG-18 trial
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study
(
- Contribution to journal › Article
- 2018
-
Mark
Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes
(
- Contribution to journal › Letter
-
Mark
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
(
- Contribution to journal › Article
-
Mark
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma
(
- Contribution to journal › Article